|drug245||Antibody testing Wiki||0.71|
|drug2400||Pemziviptadil (PB1046) Wiki||0.71|
|drug1828||Low Dose (10 mg) Control Wiki||0.71|
|D011654||Pulmonary Edema NIH||0.41|
|D011665||Pulmonary Valve Insufficiency NIH||0.27|
|D006333||Heart Failure NIH||0.25|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.06|
|D055371||Acute Lung Injury NIH||0.06|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.05|
|D003141||Communicable Diseases NIH||0.05|
|D018352||Coronavirus Infections NIH||0.02|
There are 2 clinical trials
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression. In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma. Only patients with moderate to severe disease at risk for transfer to intensive care unit or patients at the intensive care unit with limited treatment options will be treated.
Description: Serious adverse events during the study period include transfusion reaction (fever, rash), transfusion related acute lung injury (TRAU) , transfusion associated circulatory overload (TACO) , transfusion related infectionMeasure: Serious adverse events in convalescent plasma treated patients Time: From baseline (enrolment) to 24 hours follow-up
Description: Change in SARS-CoV2 quantitative in nasopharyngeal swabMeasure: Virologic clearance in nasopharyngeal swab of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Description: Transfer to ICUMeasure: Transfer to ICU Time: at Baseline (admission to Covid-ward) until day 28
Description: in-hospital deathMeasure: in-hospital death Time: at Baseline (admission to Covid-ward) until day 28
Description: Change in SARS-CoV2 quantitative in plasmaMeasure: Virologic clearance in plasma of convalescent plasma treated patients Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
Description: Duration of hospitalisationMeasure: Time to discharge from hospital after enrolment Time: at Baseline (admission to Covid-ward) until discharge (approx. 28 days)
Description: Rise of SARS-CoV-2 antibody titers (on day 1, 7, 14 and 28)Measure: Humoral immune response Time: at Baseline (admission to Covid-ward), day -1 (before plasma), day 1 (after plasma), day7, day 14, day 28
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Description: Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapyMeasure: Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports